Why the study?
Diabetic cardiomyopathy causes a detrimental shift in mitochondrial dynamics contributing to cardiomyocyte apoptosis and cardiac dysfunction, but the impact and mechanisms of modulating these dynamics remained to be evaluated.
Does modulating mitochondrial dynamics with Mdivi-1 or Ginsenoside Rg1 improve cardiac function in a mouse model of diabetic cardiomyopathy?
Does modulating mitochondrial dynamics with Mdivi-1 or Ginsenoside Rg1 improve cardiac function in a mouse model of diabetic cardiomyopathy?
Pharmacological modulation of mitochondrial dynamics by inhibiting fission or promoting fusion ameliorates left ventricular dysfunction and reduces cell death in a preclinical model of diabetic cardiomyopathy.
Should not yet change DCM practice; leaves open whether fission or fusion modulation translates to patients.
Diabetic cardiomyopathy (DCM) triggers a detrimental shift in mitochondrial dynamics, characterized by increased fission and decreased fusion, contributing to cardiomyocyte apoptosis and cardiac dysfunction. This study investigated the impact of modulating mitochondrial dynamics on DCM outcomes and underlying mechanisms in a mouse model. DCM induction led to upregulation of fission genes (Drp1, Mff, Fis1) and downregulation of fusion genes (Mfn1, Mfn2, Opa1). Inhibiting fission with Mdivi-1 or promoting fusion with Ginsenoside Rg1 preserved cardiac function, as evidenced by improved left ventricular ejection fraction (LVEF), fractional shortening (FS), and E/A ratio. Both treatments also reduced infarct size and attenuated cardiomyocyte apoptosis, indicated by decreased caspase-3 activity. Mechanistically, Mdivi-1 enhanced mitochondrial function by improving mitochondrial membrane potential, reducing reactive oxygen species (ROS) production, and increasing ATP generation. Ginsenoside Rg1 also preserved mitochondrial integrity and function under hypoxic conditions in HL-1 cardiomyocytes. These findings suggest that restoring the balance of mitochondrial dynamics through pharmacological interventions targeting either fission or fusion may offer a promising therapeutic strategy for mitigating MI-induced cardiac injury and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Zhi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: